Cohort Study on People Who Inject Drugs in Senegal

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

208 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-08-24

Study Completion Date

2021-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of the CoDISEN cohort study is to propose a model of prevention and care for HIV and viral hepatitis adapted to the needs of people who inject drugs (PWID) in Dakar, Senegal.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Universal Coverage of Antiretroviral Treatment in Senegal

NCT03880006

HIV/AIDS

COMPLETED NA

HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease

NCT01141205

Aids, Cdc Group I

COMPLETED PHASE1

Epidemiological Study of HIV in the South African National Defense Force

NCT00341887

HIV

TERMINATED

Examining HIV Treatment Adherence During Early Disease

NCT02419066

Medication Adherence HIV

COMPLETED

Nutritional Support for HIV-Tuberculosis Co-infected Adults in Senegal, West Africa

NCT03711721

HIV and Tuberculosis Co-infection

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

THE UNODC estimated the number of consumers of injectable drugs at 1,02 millions in 2012 in Africa among which 12,1 % lived with HIV. Prevalences of HIV, chronic hepatitis C and B among people who inject drugs remain little documented in Sub-Saharan Africa. The transmission of HCV in Africa is mainly hospital-borne, bound to a precarious transfusional and therapeutic safety. However, the transmission by intravenous drug use emerges as a new stake in public health in urban areas. The report of a strong HIV prevalence in the population of PWID in the sub-region ( for example, In 2007, in the Cape Verde, prevalence of the HIV was 14 % in emprisoned PWID against 0,8 % in the general population) contributed to assert the reality of the use of intravenous drugs in the region and the vulnerability of this population. Senegal, a country with an concentrated HIV epidemic \[0,5 % prevalence in 2012, WHO source\] is the first country of western Africa to have measured prevalence of HIV (5,2 %), HBV (7,9 %) and HCV (23,3 %) in PWID (Study ANRS 12243). In view of these results, the Senegalese authorities introduced from October, 2011 in Dakar, activities of harm reduction by means of a mobile team of social workers and mediators allowing individual and collective activities of prevention, needle exchange program, references for care and follow-up, as well as a opioid substitution program in a methadone center (CEPIAD) located in Dakar, first of its kind in Western Africa. The objective of the present research project thus is to estimate the impact of a strategy of " test and treat " of HIV and harm reduction initiatives on the prevalence and incidence of HIV, HBV and HCV infections in an population of injectable drug consumers followed in the methadone center ( CEPIAD) of Dakar, Senegal

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Addiction HIV/AIDS Hepatitis C, Chronic Hepatitis C, Acute Hepatitis B, Chronic Hepatitis B Acute Tuberculosis Sexually Transmitted Diseases Psychiatric Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* being aged greater than or equal to 18 years or emancipated minor,
* Being or have been an injecting drug user and followed at the CEPIAD (methadone program)
* Living in the Dakar region for at least three months,
* Consenting to the study after individual information.